VivoSeq
Oncology

Myeloma

0

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Myeloma is an early-stage landscape with 0 programs across 2 companies. The most active players are Cartesian Therapeutics, LifeTime Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cartesian Therapeutics

0 programs

PreclinicalL

LifeTime Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

26

clinical trials

Completed14 · 54%
Unknown status4 · 15%
Terminated3 · 12%
Recruiting2 · 8%
Active, not recruiting1 · 4%
Withdrawn1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

26 trials

A New Study Evaluating the Activity of Modular CAR T for mYeloma
Recruiting·UUniversity College, London·Phase 1·NCT04795882·27 enrolled
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Recruiting·—·Phase 2·NCT05469893·52 enrolled
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
Active, not recruiting·—·Phase 2·NCT05767359·20 enrolled
CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?
Not yet recruiting·XXuzhou Medical University·Phase 2·NCT07070934·60 enrolled
Bendamustine and Melphalan in Myeloma
Completed·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT03187223·120 enrolled
Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant
Completed·UUniversity of Pennsylvania·Phase 2·NCT01426828·40 enrolled
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
Completed·SWOG Cancer Research Network·Phase 3·NCT00002548·899 enrolled
Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients
Completed·GGruppo Italiano per lo Studio del Mieloma Multiplo·Phase 3·NCT00232934·400 enrolled
Autophagy Induction After Bortezomib for Myeloma
Completed·—·Phase 1·NCT01594242·11 enrolled
Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance
Completed·UUniversity Medical Center Groningen·Phase 2·NCT02467010·73 enrolled
IFM 99-02 Thalidomide in Myeloma
Completed·UUniversity Hospital, Toulouse·Phase 3·NCT00222053·800 enrolled
Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT
Completed·UUniversity of Rochester·Phase 1·NCT04862676·29 enrolled
Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma
Completed·SSwiss Cancer Institute·Phase 2·NCT02188537·34 enrolled
Selinexor, Cyclophosphamide and Prednisone in Myeloma
Completed·UUniversity of Leeds·Phase 2·NCT06212596·66 enrolled
Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.
Completed·KKarin B. Ø. Dieperink·N/A·NCT05163405·10 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)